Holdings
Trails Edge Capital Partners, LP
As of Sep 30, 2026, Trails Edge Capital Partners, LP reported 36 positions worth US$666M. Largest: LB Pharmaceuticals Inc, BioMarin Pharmaceutical Inc. and Nurix Therapeutics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| LB Pharmaceuticals Inc | 1.15M | US$44.1M | −374K | Sep 30, 2026 |
| BioMarin Pharmaceutical Inc. | 667K | US$40M | +155K | Sep 30, 2026 |
| Nurix Therapeutics, Inc. | 1.57M | US$37.3M | no change | Sep 30, 2026 |
| Obsidian Therapeutics, Inc. | 2.5M | US$34.3M | new | Sep 30, 2026 |
| Immunocore Holdings plc | 1.06M | US$32.2M | new | Sep 30, 2026 |
| 4D Molecular Therapeutics, Inc. | 2.23M | US$31.9M | no change | Sep 30, 2026 |
| Design Therapeutics, Inc. | 2.5M | US$31.4M | +499K | Sep 30, 2026 |
| Cytokinetics, Incorporated | 470K | US$31M | +182K | Sep 30, 2026 |
| First Tracks Biotherapeutics, Inc. | 814K | US$28.8M | −700K | Sep 30, 2026 |
| Sensei Biotherapeutics, Inc. | 942K | US$28M | +426K | Sep 30, 2026 |